Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis greenmarketreport Views: 214

-

The maturing psychedelics industry has watched superstar companies come and go. It happens in nascent industries, especially one aligned with federally illegal substances.

But even without any revenue-making product, which is standard operating procedure for most of the top psychedelics companies, there are still some interesting movements by companies to expand research and development, make new discoveries through partnerships, and challenge investors to understand the landscape of winners and losers.

Let’s take a look at what’s happening with three psychedelics companies who recently filed earnings reports:

Filament Health (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS)

Filament Health filed its third quarter financial results on Nov. 10. In its announcement, the company highlighted that it extended its cash runway with $2.5 million in fresh financing, freeing up more drug development space and more potential patent accrual. It already had five patents from the Canadian Intellectual Property Office and three in the U.S. as of August. The company obtained a fourth patent in the U.S. on Nov. 9, bringing the company’s total to nine patents overall, Filament Health Chief Marketing Officer Anna Cordon confirmed to Green Market Report in an email.

Patents are gold in the bank for any psychedelics development company and a sure sign of ongoing financial health for the company. Filament is estimated to actually make $100,000 in revenue this quarter (through Dec. 31), the company has been spooking investors with a steady market cap reduction over the year, from a high of $41.98 million in September 2021 to $10.48 million this September.

Cybin (NEO: CYBN) (NYSE: CYBN)

Cybin filed its financial results for the second quarter of fiscal year 2023 on Nov. 14. The company was able to issue and sell up to an additional $28.9 million of common shares, which allows Cybin to access additional cash for growth opportunities and working capital.

Cybin, too, is finding gold in their patent work. They strengthened their drug discovery platform and intellectual property portfolio through multiple licensing arrangements that have broadened the company’s intellectual property reach and created a path for potential future pipeline expansion. Cybin now has access to more than 35 patents and applications through a combination of internal filings and licensing arrangements.

Atai Life Sciences (Nasdaq: ATAI)

Atai filed its third quarter financial results on Nov. 10. The company demonstrated its ability to execute on various clinical trials and is working on a direct-to-brain delivery of various compounds that has wide-ranging applications in the psychedelics industry.

Atai is still burning through money for research and development expenses—up to $19 million and $52.4 million for the three and nine months ended Sept. 30, respectively, as compared to $13.4 million and $35 million for the same prior year periods.

The company still ended the quarter with $304 million in cash, an almost unheard of amount among other top-tier psychedelics companies, but down $58 million from earlier in the year. The company used that cash to pay for operating activities, additional investments in platform companies, and other expenses. Atai also secured a loan agreement in August of up to $175 million. That loan money is expected to extend their positive financial health through 2025.

Just a week after these financial results were released, Atai announced it has initiated a clinical study with Massachusetts General Hospital to utilize a neuroimaging method to identify neuroplasticity biomarkers in patients with treatment-resistant depression undergoing intravenous ketamine treatment. The main objective of this study will be to develop a novel method to detect neuroplasticity through magnetic resonance imaging scans, electroencephalogram collection and clinical assessments.

Psychedelics Companies Report Strong Research Investment on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.